Olmesartan
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Olmesartan: From Hypertension to Migraine Disorder
One-Sentence Summary
Olmesartan is an angiotensin II receptor blocker (ARB), a class originally developed to treat hypertension. Among ten TxGNN-predicted new indications reviewed for this drug, Migraine Disorder is the strongest candidate, supported by 4 publications (including one clinical trial and a systematic review), though currently with no registered clinical trials of olmesartan specifically for this use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (inferred from ARB drug class; a formally recorded original indication was not available in this evidence pack) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.64% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold (Research Question) |
Why is This Prediction Reasonable?
Detailed mechanism of action data for olmesartan is not available in this evidence pack (a flagged high-severity data gap). Based on known pharmacology, olmesartan is an angiotensin II type-1 (AT1) receptor antagonist that blocks the renin-angiotensin-aldosterone system (RAAS), an effect it shares with the rest of the ARB class. Its established efficacy in hypertension stems from this RAAS blockade.
The link to migraine is biologically plausible: RAAS activity also contributes to cerebrovascular tone regulation and neuro-inflammation, mechanisms implicated in migraine pathophysiology. Notably, another ARB in the same class, candesartan, already has randomised controlled trial evidence supporting its use in migraine prophylaxis. This class-level precedent strengthens the case that olmesartan’s high TxGNN score is not purely a knowledge-graph artefact.
It is worth noting that TxGNN’s single highest-ranked prediction for this drug, Prinzmetal angina, was explicitly assessed as lacking mechanistic support (coronary vasospasm is not a RAAS-driven process) and carries no supporting evidence. Migraine disorder was therefore selected for this report as the most defensible candidate among the ten predictions reviewed, on the basis of both existing human data and class-level analogy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16618270 | 2006 | Clinical Trial | Headache | Explored the effects of olmesartan on frequency and severity of migraine attacks in patients with comorbid hypertension/prehypertension. |
| 31515634 | 2019 | Review/Meta-analysis | Current Pain and Headache Reports | Systematic review of ACE inhibitors and ARBs in episodic migraine prophylaxis; identifies gaps in research and guidance for future trials. |
| 16942482 | 2006 | Review | Headache | Discusses the relationship between olmesartan, blood pressure control, and migraine. |
| 12582288 | 2003 | Review | Nursing | General new-drug review briefly noting olmesartan; limited migraine-specific content. |
UK Market Information
Olmesartan is not currently marketed in the United Kingdom according to this evidence pack, with no marketing authorisations recorded (0 licences).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: TFDA/SmPC warning and contraindication data, and full drug interaction data, were flagged as data gaps in this evidence pack — see Next Steps.)
Conclusion and Next Steps
Decision: Hold (Research Question)
Rationale: A single completed trial and supportive narrative/systematic reviews suggest ARBs, including olmesartan, may reduce migraine frequency in hypertensive patients, but no dedicated migraine-specific RCT exists and olmesartan is not currently marketed in the UK. This is a hypothesis worth formal investigation rather than a basis for clinical use at this stage.
To proceed, the following is needed:
- A dedicated RCT evaluating olmesartan for migraine prophylaxis, ideally in normotensive patients, to separate the effect from blood-pressure lowering
- SmPC-level warnings, contraindications and full drug interaction data (currently a blocking data gap)
- Confirmed mechanism of action data linking RAAS blockade to neurovascular/migraine pathways beyond blood pressure effects
- UK marketing authorisation status review, should development proceed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.